Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology

This publication has 45 references indexed in Scilit:

• Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast
  Pharmacological Research, 2022
• CREB family: A significant role in liver fibrosis
  Biochimie, 2019
• Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench
  Hepatology, 2019
• Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways
  Life Sciences, 2019
• Burden of liver diseases in the world
  Journal of Hepatology, 2019
• Neuronal cAMP/PKA Signaling and Energy Homeostasis
  2018
• A small, steady, rapid and selective TICT based fluorescent HSA sensor for pre-clinical diagnosis
  Sensors and Actuators B: Chemical, 2018
• Role of cAMP and phosphodiesterase signaling in liver health and disease
  Cellular Signalling, 2018
• Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis
  Clinical Gastroenterology and Hepatology, 2014
• Future directions in phosphodiesterase drug discovery
  Bioorganic & Medicinal Chemistry Letters, 2012